Latest news

discover and share

In this newsletter, you'll find out about the most commun genetic defect in hPSCs found on the chromosome 20q11.21. We'll explain why it is an important abnormality to detect and provide you with advice on the technologies you should be using to that effect. Read on by downloading the pdf below.

Big milestone for the team here at Stem Genomics: we have received the ISO 9001:2015 certification! This is an internationally recognised standard that ensures that our products and services meet our clients’ needs through an effective quality management system. Although it represented a rather colossal effort, everyone involved was driven by the conviction that implementing a system of continual improvement in all our processes would result in numerous benefits for our clients. This is the list of reasons that drove us to take on this journey: - Commitment to providing high-quality and consistent services to our existing and future clients - Ensure our clients’ satisfaction in relation with the efficiency of our operations: we have put futureproof processes in place to withstand the constantly changing environment we navigate in, - Show compliance with regulatory requirements and the evolving needs of our customers and their markets so we can better meet them, - Anticipate and prevent non-conformities, which we can’t afford to have with the demanding markets we address, - Remain competitive and relevant with our product and service developments operating within an established framework inspired by best business practices, - Involve and unite the team behind a shared goal. We are confident this recognised quality management system will enable our biotechnology company to provide the peace of mind our clients require when using our tests and services.

Why it is important to routinely test your iPSC lines for genomic abnormalities… and what you risk if you don’t! Find out why you should regularly test throughout the cell culture process, at which rate and get help on identifying the right technologies to keep time and costs under control. Our October newsletter will provide you with the answers and the reassurance on quality control that you need. Press the download button below to find out more!

The discovery and recent advances in the CRISPR/Cas9 gene-editing technology have profoundly reshaped the field of genome engineering and allowed the generation of a wide range of mutant cell lines at an unprecedented rate. However, CRISPR/Cas9 gene editing in hPSCs can also pose a threat to the overall genomic integrity. Why? To know more, have a look at our July newsletter!

Stem cells are the heart of many of tomorrow personalized therapies. Join us at the most comprehensive meeting in stem cell science, the ISSCR 2021. It will take place virtually from 21 to 26 June 2021. Discover our services for your stem cell research projects and meet us at our booth during this virtual event! We are eager to answer any questions you might have.

DIGITAL - PCR
Digital PCR is the most accurate PCR method for assessing the genetic integrity of stem cells through the detection of Copy Number Variants (CNVs). At Stem Genomics, we help you to assess the genetic integrity of your stem cell lines with digital PCR-based tests designed to suit your organization and the specific features of your cell lines. If you want to learn more, download the Newsletter.

The most recurrent abnormality in hPSCs
Many of you asked for a test that would focus on the most common abnormality in hPSCs. So, we made it! You can now detect specifically the sub-karyotypic 20q11.21 amplification, which represents >20% of recurrent genomic abnormalities in hPSCs, with a rapid, sensitive and easy-to-use digital PCR kit.

iCS-digital kit and software
Stem Genomics diversifies its offer by launching the iCS-digital TM PSC kit, allowing you to perform this test, already offered in service for more than 2 years, in your facilities. The iCS-digital TM PSC kit is a precise, fast and sensitive digital PCR test for the detection of more than 90% of the recurrent genomic abnormalities in hPSCs. The iCS-digital TM PSC kit includes eight multiplexed PCR assays that allow the reliable analysis of the 24 regions with the most frequent Copy Number Variations (CNVs) reported in hPSCs. The kit also includes a validated normal genomic DNA control (XY). Data processing, statistical analysis, and graphical representation of the results can be performed in an automated and explicit way using the iCS-digital TM software provided online by Stem Genomics to help users with data interpretation.

The future starts here, with us! We are exhibiting at ISSCR 2020 from 23 to 27 June 2020. Discover our services and meet us during the virtual ISSCR annual meeting. We can help you secure your stem cell research; take advantage of our free* test offer to try our services by completing the request form available at our booth in Exhibit Hall 4. *This offer is reserved for new customers

The iCS-digital test now published  in Stem Cell Reports
Recurrent Genetic Abnormalities in Human Pluripotent Stem Cells: Definition and Routine Detection in Culture Supernatant by Targeted Droplet Digital PCR In the article published in Stem Cell Reports in January 2020, Assou et al. demonstrate the interest of the iCS-digital TM test for routine human pluripotent stem cell (hPSC) screening. Thanks to the specificity of the digital PCR (dPCR) probe panel, the simplicity of sample collection, and the accuracy of the ddPCR technology, this test allows the fast and straightforward monitoring of hPSC integrity. This innovative test can change how hPSC quality controls are implemented for basic research and cell therapy by increasing the test frequency to secure cell productions and avoid expensive and time-consuming cell cultures. The iCS-digital TM test is exclusively provided by Stem Genomics as a full service. To request technical information or ask for a quote, please follow this link : Link to the publication Discover the test and request a quote

The iCS-digital TM test is a straightforward method for screening human pluripotent stem cell (hPSC) clones after CRISPR gene editing
The iCS-digital TM test offers fast and reliable detection of the most common genomic abnormalities in CRISPR/Cas9-edited hPSCs By combining human pluripotent stem cells (hPSCs) and the CRISPR/Cas9 genome editing technology, new opportunities are created to study disease mechanisms, with enormous therapeutic potential. Despite the progress in genome engineering, the CRISPR gene editing process consists of major sequential and potentially stressful events, such as clonal expansion, FACS enrichment, drug selection, manual colony picking or stressful single-cell dissociation. By triggering selective pressures on cells, these procedures could favour the generation and selection of genetically abnormal hPSCs, and consequently render these cells unsuitable for further use. Therefore, efficient and rapid screening of CRISPR-modified hPSCs is essential before their use for research purposes or clinical applications. Discover the test and request a quote

iCS-digital: A method for monitoring hPSC genome integrity that detects more than 90% of recurrent genomic abnormalities. The test is rapid (2-3 days), convenient (full service), straightforward, and can be performed using cell culture supernatant. It is particularly suitable for the routine monitoring of cell lines in culture and for screening genetically stable clones (e.g., CRISPR-edited iPSC clones, patient-derived iPSC clones…).

The Ed-digital PCR test directly informs on the presence and number of transgenes copies  inserted in the genome of CRISPR-edited cells
Thanks to its flexibility and ability to achieve precise targeting, the CRISPR system is a powerful gene editing tool for various molecular biology applications. Precise control of the transgene integration is a major challenge for human cell research biosafety. Despite the improvement of CRISPR specificity, a significant proportion of transgenes integrates at unintended sites. These off-target insertions can cause genomic alterations that may disrupt normal cell functions with dramatic consequences on research outcomes. Therefore, it is crucial to verify the transgene presence at the desired genome site using PCR or sequencing, and also to confirm the absence of any possible additional unwanted insertion using Ed-digital, Stem Genomics digital PCR test for transgene copy number quantification. Ed-digital services The Ed-digital test allows the detection of the number of transgene copies present in the genome of gene-edited cells using digital PCR. Ed-digital targets common resistance cassettes (puromycin, neomycin) as well as the fluorescent reporter gene mCherry. Examples of Ed-digital applications in gene-edited induced pluripotent stem cell (iPSC) lines Analysis of transgene integration in iPSC lines (graph on the left): A. Determination of the number of neomycin gene copies in two iPSC samples. The first sample carries two copies and the second one single copy of the transgene. B. Determination of puromycin gene copies in two iPSC samples. The first one carries two copies and the other one displays mosaic integration (n=2.5) of the transgene. Discover the test and request a quote

straightforward method for monitoring hPSC genome integrity
Now online “Recurrent genetic abnormalities in human pluripotent stem cells: definition and routine detection in culture supernatant by targeted droplet digital PCR” by Assou et al. The unique features of human pluripotent stem cells (hPSCs) open new opportunities for disease modeling, drug discovery and the development of cell-based therapies. However, genetic abnormalities can accumulate during the generation, long-term maintenance or during genome editing of these cells. Therefore, it is crucial to detect these abnormalities as soon as they appear to guaranty the safe and proper use of hPSCs in clinical practice and in research. To address this issue, Assou et al. performed an exhaustive study by combining data from publications describing the occurrence of hPSC aberrations during in vitro culture. Based on this large meta-analysis, a test called iCS-digital (in culture supernatant-digital PCR) has been designed consisting in a panel of digital PCR probes that target the most recurrent abnormalities identified by these studies. Thanks to the precision of the digital PCR technology, the iCS-digital test allows the sensitive, precise and absolute quantification of copy number variations (CNVs) and the detection of anomalies that are below the G-banding method resolution, especially the sub-karyotypic 20q11.21 hotspot. Using the iCS-digital test, Assou et al. could monitor cell integrity through regular screenings, and record the moment where genomic aberrations appeared. Furthermore, the iCS-digital test presents the advantage of using cell culture supernatant instead of intact cells as a DNA source, bypassing the inconvenience of dedicating a certain fraction of cell material for control quality testing. To conclude, Assou et al. demonstrated the interest of the iCS-digital test for routine hPSC screening, thanks to the simplicity of the collection procedure, the rapidity of the test, and the accuracy of the digital PCR technology. This innovative test can change how hPSC quality control is implemented for their use in basic research, regenerative medicine, and can contribute to secure genome editing workflows. The iCS-digital TM test is exclusively provided by Stem Genomics as a full service. For more information and quotations, please follow these links: Download the publication Discover the test and request a quote

The iCS-digital TM test was used to evaluate the genomic integrity of hiPSCs in the work punblished by Neri et al. in Nature Communications in April 2019: "Human pre-valvular endocardial cells derived from pluripotent stem cells recapitulate cardiac pathophysiological valvulogenesis". https://www.nature.com/articles/s41467-019-09459-5

Stem Genomics will attend the First France-USA Stem Cell Symposium that will take place on June 25th 2019, the day preceding the ISSCR meeting, at the Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at the University of Southern California, Los Angeles. We look forward meeting you there! Don't hesitate to request a meeting in advance.

new website Stem Genomics made by Caconcept
Stem Genomics has launched its new website and we are excited to present its new look. Our new website provides a clear message about who we are, what we stand for and about our solutions. The website also boasts a clean design and intuitive and consistent site-wide navigation system with improved menu functionalities that direct you to the most relevant information for your needs. It is also fully responsive on mobile devices, and the website pages are easy to navigate using a wide range of web browsers and portable devices.

Stay informed

Subscribe to our newsletter